Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
DOI: | 10.1089/adt.2023.013 |
Texto Completo: | http://dx.doi.org/10.1089/adt.2023.013 http://hdl.handle.net/11449/245642 |
Resumo: | Candidosis is one of the most frequent opportunistic infections and exhibits variable clinical presentations, including oral localized forms. Drugs affecting the renin-angiotensin system targets inhibit secreted aspartic proteases from Candida albicans. The objective of the study was to evaluate whether losartan has antimicrobial action against C. albicans biofilms. Biofilms were treated with losartan or aliskiren (for comparison) for 24 h. Metabolic activity of viable cells and growth inhibition of C. albicans biofilms were assessed using XTT [2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenyl-Amino)Carbonyl]-2H-Tetrazolium Hydroxide] and colony-forming unit assays, respectively. In addition, the cytotoxicity of the drugs on human cells was evaluated using the AlamarBlue assay. Both drugs decreased fungal viability at all concentrations. In addition, all concentrations of losartan inhibited the growth of C. albicans biofilm, ranging from 47% to 88.5%, whereas aliskiren showed inhibition from 1 to 10 mg/mL, which ranged from 16% to 97.6%. Furthermore, at certain concentrations, these drugs maintained the viability of human cells. Losartan and aliskiren have fungistatic and fungicidal action against C. albicans biofilms and are compatible with human cells. Therefore, these antihypertensive drugs can be repurposed to interfere with the metabolism and development of Candida biofilms, which are widely associated with clinical forms of candidosis, including oral localized forms such as denture stomatitis. |
id |
UNSP_aa111be71cbb03c5351b10ba73ba8230 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/245642 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosisaliskirendenture stomatitislosartandrug repositioningCandida albicansCandidosis is one of the most frequent opportunistic infections and exhibits variable clinical presentations, including oral localized forms. Drugs affecting the renin-angiotensin system targets inhibit secreted aspartic proteases from Candida albicans. The objective of the study was to evaluate whether losartan has antimicrobial action against C. albicans biofilms. Biofilms were treated with losartan or aliskiren (for comparison) for 24 h. Metabolic activity of viable cells and growth inhibition of C. albicans biofilms were assessed using XTT [2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenyl-Amino)Carbonyl]-2H-Tetrazolium Hydroxide] and colony-forming unit assays, respectively. In addition, the cytotoxicity of the drugs on human cells was evaluated using the AlamarBlue assay. Both drugs decreased fungal viability at all concentrations. In addition, all concentrations of losartan inhibited the growth of C. albicans biofilm, ranging from 47% to 88.5%, whereas aliskiren showed inhibition from 1 to 10 mg/mL, which ranged from 16% to 97.6%. Furthermore, at certain concentrations, these drugs maintained the viability of human cells. Losartan and aliskiren have fungistatic and fungicidal action against C. albicans biofilms and are compatible with human cells. Therefore, these antihypertensive drugs can be repurposed to interfere with the metabolism and development of Candida biofilms, which are widely associated with clinical forms of candidosis, including oral localized forms such as denture stomatitis.Univ Sao Paulo, Bauru Sch Dent, Dept Surg Stomatol Pathol & Radiol, Bauru, BrazilUniv Sao Paulo, Integrated Res Ctr, Bauru Sch Dent, Bauru, BrazilUniv Sao Paulo, Bauru Sch Dent, Dept Biol Sci, Bauru, BrazilSao Paulo State Univ UNESP, Sch Dent, Dept Basic Sci, Immunopharmacol Lab, Aracatuba, BrazilUniv Sao Paulo, Bauru Sch Dent, Dept Surg Stomatol Pathol & Radiol, Alameda Dr Otavio Pinheiro Brisolo 9-75, BR-17012901 Bauru, SP, BrazilSao Paulo State Univ UNESP, Sch Dent, Dept Basic Sci, Immunopharmacol Lab, Aracatuba, BrazilMary Ann Liebert, IncUniversidade de São Paulo (USP)Universidade Estadual Paulista (UNESP)Lara, Vanessa SoaresSilva, Rafaela Alves daFerrari, Tatiane PonteadoSantos, Carlos Ferreira dosOliveira, Sandra Helena Penha de [UNESP]2023-07-29T12:00:51Z2023-07-29T12:00:51Z2023-05-25info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article9http://dx.doi.org/10.1089/adt.2023.013Assay and Drug Development Technologies. New Rochelle: Mary Ann Liebert, Inc, 9 p., 2023.1540-658Xhttp://hdl.handle.net/11449/24564210.1089/adt.2023.013WOS:000993051500001Web of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengAssay And Drug Development Technologiesinfo:eu-repo/semantics/openAccess2024-09-19T14:02:46Zoai:repositorio.unesp.br:11449/245642Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestrepositoriounesp@unesp.bropendoar:29462024-09-19T14:02:46Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis |
title |
Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis |
spellingShingle |
Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis Lara, Vanessa Soares aliskiren denture stomatitis losartan drug repositioning Candida albicans Lara, Vanessa Soares aliskiren denture stomatitis losartan drug repositioning Candida albicans |
title_short |
Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis |
title_full |
Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis |
title_fullStr |
Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis |
title_full_unstemmed |
Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis |
title_sort |
Losartan Plays a Fungistatic and Fungicidal Activity Against Candida albicans Biofilms: Drug Repurposing for Localized Candidosis |
author |
Lara, Vanessa Soares |
author_facet |
Lara, Vanessa Soares Lara, Vanessa Soares Silva, Rafaela Alves da Ferrari, Tatiane Ponteado Santos, Carlos Ferreira dos Oliveira, Sandra Helena Penha de [UNESP] Silva, Rafaela Alves da Ferrari, Tatiane Ponteado Santos, Carlos Ferreira dos Oliveira, Sandra Helena Penha de [UNESP] |
author_role |
author |
author2 |
Silva, Rafaela Alves da Ferrari, Tatiane Ponteado Santos, Carlos Ferreira dos Oliveira, Sandra Helena Penha de [UNESP] |
author2_role |
author author author author |
dc.contributor.none.fl_str_mv |
Universidade de São Paulo (USP) Universidade Estadual Paulista (UNESP) |
dc.contributor.author.fl_str_mv |
Lara, Vanessa Soares Silva, Rafaela Alves da Ferrari, Tatiane Ponteado Santos, Carlos Ferreira dos Oliveira, Sandra Helena Penha de [UNESP] |
dc.subject.por.fl_str_mv |
aliskiren denture stomatitis losartan drug repositioning Candida albicans |
topic |
aliskiren denture stomatitis losartan drug repositioning Candida albicans |
description |
Candidosis is one of the most frequent opportunistic infections and exhibits variable clinical presentations, including oral localized forms. Drugs affecting the renin-angiotensin system targets inhibit secreted aspartic proteases from Candida albicans. The objective of the study was to evaluate whether losartan has antimicrobial action against C. albicans biofilms. Biofilms were treated with losartan or aliskiren (for comparison) for 24 h. Metabolic activity of viable cells and growth inhibition of C. albicans biofilms were assessed using XTT [2,3-Bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenyl-Amino)Carbonyl]-2H-Tetrazolium Hydroxide] and colony-forming unit assays, respectively. In addition, the cytotoxicity of the drugs on human cells was evaluated using the AlamarBlue assay. Both drugs decreased fungal viability at all concentrations. In addition, all concentrations of losartan inhibited the growth of C. albicans biofilm, ranging from 47% to 88.5%, whereas aliskiren showed inhibition from 1 to 10 mg/mL, which ranged from 16% to 97.6%. Furthermore, at certain concentrations, these drugs maintained the viability of human cells. Losartan and aliskiren have fungistatic and fungicidal action against C. albicans biofilms and are compatible with human cells. Therefore, these antihypertensive drugs can be repurposed to interfere with the metabolism and development of Candida biofilms, which are widely associated with clinical forms of candidosis, including oral localized forms such as denture stomatitis. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-07-29T12:00:51Z 2023-07-29T12:00:51Z 2023-05-25 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1089/adt.2023.013 Assay and Drug Development Technologies. New Rochelle: Mary Ann Liebert, Inc, 9 p., 2023. 1540-658X http://hdl.handle.net/11449/245642 10.1089/adt.2023.013 WOS:000993051500001 |
url |
http://dx.doi.org/10.1089/adt.2023.013 http://hdl.handle.net/11449/245642 |
identifier_str_mv |
Assay and Drug Development Technologies. New Rochelle: Mary Ann Liebert, Inc, 9 p., 2023. 1540-658X 10.1089/adt.2023.013 WOS:000993051500001 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Assay And Drug Development Technologies |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
9 |
dc.publisher.none.fl_str_mv |
Mary Ann Liebert, Inc |
publisher.none.fl_str_mv |
Mary Ann Liebert, Inc |
dc.source.none.fl_str_mv |
Web of Science reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
repositoriounesp@unesp.br |
_version_ |
1822183860018872320 |
dc.identifier.doi.none.fl_str_mv |
10.1089/adt.2023.013 |